Testosterone therapy and dermatologic conditions in transgender men : a systematic review and meta-analysis
2
2
Issued Date
2023
Copyright Date
2023
Resource Type
Language
eng
File Type
application/pdf
No. of Pages/File Size
ix, 95 leaves : ill.
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Mahidol University
Bibliographic Citation
Thematic Paper (M.Sc. (Medicine))--Mahidol University, 2023
Suggested Citation
Apichaya Tannirandorn Testosterone therapy and dermatologic conditions in transgender men : a systematic review and meta-analysis. Thematic Paper (M.Sc. (Medicine))--Mahidol University, 2023. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115353
Title
Testosterone therapy and dermatologic conditions in transgender men : a systematic review and meta-analysis
Author(s)
Abstract
Testosterone alters the prevalence of dermatologic conditions found in transgender men. The prevalence of these dermatologic conditions varied greatly between studies. The objective of this research aimed to find the prevalence of acne, hypertrichosis in androgen-sensitive areas (HAAs), and androgenetic alopecia (AGA) in transgender men receiving testosterone therapy. A literature search was conducted via PubMed, Embase, along with reference lists to identify relevant studies published through February 15th, 2023. Meta-analysis was applied to acne, hypertrichosis, and alopecia in transgender men. Statistical tests for heterogeneity as well as subgroup analysis were applied. A total of 1,792 studies were identified from all sources. After duplicates were removed and records screened, this resulted in 18 eligible studies which were published during 1989 - 2023. The pooled short-term and long-term prevalence proportions of acne were 0.68 (95% CI, 0.37 - 0.92) and 0.63 (95% CI, 0.36 - 0.86), respectively. The acne severity scores peaked at 6 months. There was no statistically significant association between the duration of testosterone treatment and acne. Different dosages of testosterone treatment did not lead to bothersome acne. The pooled short-term and long-term prevalence proportions of HAAs were 0.87 (95% CI, 0.66 - 0.99) and 0.75 (95% CI, 0.24 - 1.00), respectively. The pooled mean modified Ferriman-Gallwey scores were 12.83 (95% CI, 8.33 - 17.33) at 12 months. No study reported the association between the duration of testosterone and HAAs. One study found that different dosages of testosterone contributed to different prevalence of facial hair growth at 6 months. The pooled short-term and long-term prevalence proportions of AGA were 0.22 (95% CI, 0.10 - 0.37) and 0.44 (95% CI, 0.11 - 0.80), respectively. The AGA severity scores increased over 12 months. No study compared the dosage of testosterone with AGA. One study found that the duration of testosterone therapy was significantly associated with AGA with adjusted odds ratio = 1.05 and 95% CI 1.01 - 1.09. Limitations: A small number of studies were included in this meta-analysis with high heterogeneity. The sources of heterogeneity were not completely explored. Moreover, publication bias was not assessed. Implication of the thematic paper: Testosterone affects the occurrence of dermatologic conditions found in transgender men. Our results could be beneficial among healthcare providers and the transgender population.
Degree Name
Master of Science
Degree Level
Master's degree
Degree Department
Faculty of Medicine Ramathibodi Hospital
Degree Discipline
Medicine
Degree Grantor(s)
Mahidol University